Context Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Context Therapeutics to Buy from Neutral with a $5 price target. The analyst says CTIM-76 demonstrated high potency and selectivity for CLDN6 and the drug was well tolerated in toxicity studies. The firm believes both the efficacy and safety data are consistent with what has been shown in the clinic with BNT211 and TORL-1-23, though it believes with greater potency and selectivity that CTIM-76 could be more effective than competitors at lower doses.